Immunicum applies for listing on the Nasdaq Stockholm main market

Gothenburg, Sweden, May 2, 2016. Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Company has applied for listing of its shares on the Nasdaq Stockholm main market. As part of the process Immunicum's shares have been approved for listing on the Nasdaq First North Premier ("First North Premier").

CEO Jamal El-Mosleh comments:

"To apply for a listing on the Stockholm Stock Exchange main market is a natural step in Immunicum's development. The listing and the access to the institutional capital market go hand in hand with our ambitious operational goals.

We work continuously with the processes and procedures required for the listing on the Stockholm Stock Exchange main market. As part of the preparations, the Company's shares are to be traded on First North Premier, which means that we already meet many of the requirements for communication and reporting that apply on the main market."

First day of trading in Immunicum's shares on First North Premier will be May 4, 2016. Short name and ISIN code will remain unchanged. Trading in Immunicum's shares on the Nasdaq Stockholm main market is expected to commence by the end of 2016.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The Company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).

www.immunicum.com